Welcome to our dedicated page for BrightSpring Health Services SEC filings (Ticker: BTSG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BrightSpring Health Services filings document the operating results, governance, capital structure and material events of a public home- and community-based healthcare services company. Its 8-K reports include quarterly financial results, preliminary financial information, completed asset dispositions, underwriting agreements, secondary common stock offerings, company share repurchases and related registration-statement disclosures.
The company’s proxy materials cover annual meeting matters, director and governance disclosures, executive compensation and shareholder voting topics. BrightSpring filings also identify its Nasdaq-listed common stock under BTSG and its 6.75% Tangible Equity Units under BTSGU, providing formal disclosure around both operating performance and security structure.
BrightSpring Health Services (BTSG) filed a Form 4 revealing that 10% owner KKR Phoenix Aggregator L.P. sold 2,100,000 common shares on 24 June 2025 at an effective price of $21.1519 per share, generating roughly $44 million. The disposition stemmed from underwriters’ over-allotment option tied to BTSG’s recent secondary public offering at $21.75. Post-sale, KKR-affiliated entities still hold 77,096,337 shares, maintaining control. No derivatives were involved and the filing does not cite a Rule 10b5-1 plan. Each reporting person disclaims beneficial ownership beyond its economic interest.
The sale equals about 2.6 % of KKR’s prior stake. While it modestly lifts public float and may create short-term supply pressure, it leaves the sponsor’s strategic influence intact.
BrightSpring Health Services, Inc. (Nasdaq: BTSG) filed an 8-K announcing the immediate resignation of Michael McMaude as President of Hospice Services and CEO of its wholly-owned subsidiary, Abode Healthcare, effective 20 June 2025. The filing states that the departure is not due to any disagreement over operations, policies or practices.
Under a Resignation Agreement (Exhibit 10.1), Mr. McMaude will transition to a non-employee consultant role through the earlier of 26 January 2027 or earlier termination. Key economic terms include:
- Consulting compensation: $2,000 per month plus an additional $12,000 covering the first 45 days, and reimbursement of pre-approved expenses.
- Equity treatment: All outstanding unvested stock options, RSUs, and phantom shares continue to vest while he provides consulting services. Option exercise windows are extended to their original expiration dates.
- Liquidity: Equity purchased at the time of Abode’s acquisition may be sold in tranches beginning on the Effective Date, subject to securities laws.
- Restrictive covenants: Non-compete for the Consulting Period plus one year; non-solicitation and non-hire for the Consulting Period plus two years.
The company emphasizes continuity by retaining Mr. McMaude’s expertise, but his exit removes a senior leader from the hospice segment, which has been an important growth vector for BrightSpring. No other executive changes or financial impacts were disclosed, and no earnings or guidance were provided. Investors should examine whether leadership transition affects the integration and performance of Abode within the broader BrightSpring platform.